These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35668857)

  • 1. Clinical Implication of the Effect of the Production of Neutralizing Antibodies Against SARS-Cov-2 for Chronic Immune Thrombocytopenia Flare-Up Associated with COVID-19 Infection: A Case Report and the Review of Literature.
    Maekura C; Muramatsu A; Nagata H; Okamoto H; Onishi A; Kato D; Isa R; Fujino T; Tsukamoto T; Mizutani S; Shimura Y; Kobayashi T; Okumura K; Inaba T; Nukui Y; Kuroda J
    Infect Drug Resist; 2022; 15():2723-2728. PubMed ID: 35668857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report.
    Gruden G; Beggiato E; Camerino E; Capriotti S; Canepa S; Scandella M; Avolio M; Pittalunga F; Barutta F; Durazzo M
    Ther Adv Hematol; 2021; 12():20406207211011353. PubMed ID: 33995989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Sato K; Anayama M; Sumi M; Kobayashi H
    Rinsho Ketsueki; 2021; 62(12):1688-1693. PubMed ID: 35022338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Thrombocytopenic Purpura Associated with COVID-19 in a Pediatric Patient.
    Marinescu AR; Lazureanu VE; Musta VF; Nicolescu ND; Mocanu A; Cut TG; Muresan CO; Tudoran C; Licker M; Laza R
    Infect Drug Resist; 2022; 15():3405-3415. PubMed ID: 35794926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of anti-platelet factor 4 antibodies and platelet activation tests in patients with vaccine-induced immune thrombotic thrombocytopenia: Brief report on a comparison of the laboratory diagnosis and literature review.
    Hsiao PJ; Wu KL; Chen YC; Chen YL; Wang RL; Wu KA; Chan JS; Chiu CC; Huang LY; Shyu HY; Kao YH; Chuu CP
    Clin Chim Acta; 2022 Apr; 529():42-45. PubMed ID: 35167842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
    Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
    JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune thrombocytopenia and COVID-19: Case report and review of literature.
    Alonso-Beato R; Morales-Ortega A; Fernández FJH; Morón AIP; Ríos-Fernández R; Rubio JLC; Centeno NO
    Lupus; 2021 Aug; 30(9):1515-1521. PubMed ID: 34053365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group.
    González-López TJ; Bárez A; Bernardo-Gutiérrez A; Bernat S; Canaro-Hirnyk M; Entrena-Ureña L; Fernández-Fuertes F; Guinea de Castro JM; Jiménez-Bárcenas R; Pascual-Izquierdo C; Sánchez-González B; Jarque I
    Infect Dis Ther; 2023 Feb; 12(2):303-315. PubMed ID: 36520323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 infection-induced immune thrombocytopenia: a systematic review of current reports.
    Ono R; Kitagawa I
    Ann Hematol; 2024 Oct; 103(10):3921-3939. PubMed ID: 38652242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myoclonus status revealing COVID 19 infection.
    Ben Mohamed D; Zouari R; Ketata J; Nabli F; Blel S; Ben Sassi S
    Seizure; 2023 Jan; 104():12-14. PubMed ID: 36446232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccination associated severe immune thrombocytopenia.
    Shah SRA; Dolkar S; Mathew J; Vishnu P
    Exp Hematol Oncol; 2021 Jul; 10(1):42. PubMed ID: 34266487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe immune thrombocytopenia that developed immediately after COVID-19 in a school-aged patient: A case report.
    Shinno K; Banno Y; Kamimaki I
    Front Pediatr; 2023; 11():1120093. PubMed ID: 37033169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of COVID-19 vaccination on platelet counts and bleeding in children, adolescents, and young adults with immune thrombocytopenia.
    Kaicker S; Martinko K; Bussel JB
    Pediatr Blood Cancer; 2023 Jan; 70(1):e30051. PubMed ID: 36317671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune thrombocytopenia preceded by asymptomatic COVID-19 infection].
    Ochiai T; Ando J; Harada S; Hiki M; Ando M; Komatsu N
    Rinsho Ketsueki; 2021; 62(1):58-60. PubMed ID: 33551428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.